BioNTech with continued late-stage pipeline progress with candidates across immunomodulators, antibody-drug conjugates and mRNA immunotherapiesExpected 2026 oncology milestones include seven ...

BioNTech with continued late-stage pipeline progress with candidates across immunomodulators, antibody-drug conjugates and mRNA immunotherapiesExpected 2026 oncology ...

Ugur Sahin, M.D., Co-Founder and CEO of BioNTech, is a physician, immunologist and leader in the development of novel ...

With the merger's completion on January 6, 2026, CureVac's era on the public markets will end. The focus will shift entirely to integrating its clinical candidates, particularly in cancer ...

File Photo: Syringes are seen in front of displayed Biontech and Pfizer logos in this illustration taken November 10, 2020 (Reuters) BioNTech co-founder Ugur Sahin on Thursday said the frontrunner ...

In a bold step toward expanding its mRNA research and cancer treatment capabilities, BioNTech SE has announced its decision to acquire CureVac N.V. for approximately $1.25 billion in an all-stock ...

The co-founders of German drugmaker BioNTech, which was one of the first companies to develop an effective vaccine against the coronavirus, were honoured with Germany's National Prize on Tuesday. In ...

Welcome to BioNTech's First Quarter 2025 Earnings Call. I would like to hand the call over to Michael Horowicz, Director, Investor Relations. Please go ahead. Thank you. Good morning, and good ...

On Wednesday, BioNTech SE (NASDAQ:BNTX) agreed to acquire Biotheus, a clinical-stage biotechnology company focused on discovering and developing antibodies for oncological or inflammatory diseases.